What’s New in Ontosight® Terminal 1.1 A Complete Guide toRead More
What’s New in Ontosight® Terminal 1.1
Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning (ML) to bring about new risk-transfer solutions for the life science industry.
Eschborn, Germany/London, U.K., 27 July 2022
Innoplexus AG is pleased to announce that an agreement for a strategic partnership with Innovatrix Capital Ltd. has been concluded.
This exciting partnership has been struck to mutually enhance, grow and prosper within this novel business model brought forward by Innovatrix utilizing Innoplexus’ proprietary technology through its predictive clinical trial analysis engine. This engine is primarily based upon Innoplexus’ algorithms, AI and ML technology to generate a Probability of Success (PoS), which underpins Innovatrix’ suite of solutions.
Successful phase transition for clinical trials is crucial for the progression and development of new Life Science technologies with go-to-market possibilities depending on the positive outcomes of trials. This partnership will enhance the value-chain by combining Innoplexus’ deep-tech insight with risk-transfer solutions designed by Innovatrix, enabling growth for all stakeholders across Life Science research.
Innoplexus founder and CEO, Dr. Gunjan Bhardwaj points out that “Innoplexus is delighted to have entered this partnership with Innovatrix. Innoplexus being an AI leader at the forefront of technological innovation continues to strive for paradigm shifts in the entire sector.”
Innovatrix Co-founders, Qasim Akbar and Piers Clark, said “Innovatrix is very pleased to have partnered with Innoplexus who will be its exclusive provider of data and predictive analytics for the innovative Innovatrix Parametric Insurance proposition. The quality of Innoplexus’ analytics and AI services will be key elements of Innovatrix’ groundbreaking product offering to the Life Science sector designed to mitigate the risk of investment in clinical trials and thereby facilitate and encourage investment in the sector.”
About Innoplexus AG
Innoplexus is a leading global AI-based company for drug discovery and development with over 300 employees and 125+ patent applications including 60+ grants in artificial intelligence, machine learning and blockchain technologies. Innoplexus’ solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unparalleled speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, and Iselin and San Francisco, United States. For more info, please visit www.innoplexus.com
For further information contact:
Innoplexus AG
Claudia M. Hausoel, Chief Marketing Officer
E: claudia.hausoel@innoplexus.com
T: +49 (0) 151 – 6898 7478
About Innovatrix Capital Ltd.
Innovatrix is a Next-Gen Insurtech disrupter deploying cutting edge solutions for intangible risk transfer in the life sciences sector with a mission to encourage and facilitate investment in Research and Development.
Bringing together Parametric Insurance, capital markets and deep learning data science, Innovatrix’ product provides first of its kind protection against the risk of failure of clinical trials. For more information, please visit: www.innovatrixcap.co.uk
For further information contact:
Innovatrix Capital Ltd.
Piers Clark, Co-Founder and Director
E: piers@innovatrixcap.co.uk
T: +44 (0) 7714 457 450
Qasim Akbar, Co-Founder and Director
E: qasim@innovatrixcap.co.uk
T: +44 (0) 7896 734 905
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
